These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 31035017)

  • 21. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
    Aksamit T; De Soyza A; Bandel TJ; Criollo M; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R
    Eur Respir J; 2018 Jan; 51(1):. PubMed ID: 29371384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance.
    McDonnell MJ; Jary HR; Perry A; MacFarlane JG; Hester KL; Small T; Molyneux C; Perry JD; Walton KE; De Soyza A
    Respir Med; 2015 Jun; 109(6):716-26. PubMed ID: 25200914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibiotic therapy for stable non-CF bronchiectasis in adults - A systematic review.
    Fjaellegaard K; Sin MD; Browatzki A; Ulrik CS
    Chron Respir Dis; 2017 May; 14(2):174-186. PubMed ID: 27507832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis.
    White L; Mirrani G; Grover M; Rollason J; Malin A; Suntharalingam J
    Respir Med; 2012 Mar; 106(3):356-60. PubMed ID: 22204744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: a systematic review.
    Brodt AM; Stovold E; Zhang L
    Eur Respir J; 2014 Aug; 44(2):382-93. PubMed ID: 24925920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart.
    Tran TT; Vidaillac C; Yu H; Yong VFL; Roizman D; Chandrasekaran R; Lim AYH; Low TB; Tan GL; Abisheganaden JA; Koh MS; Teo J; Chotirmall SH; Hadinoto K
    Int J Pharm; 2018 Aug; 547(1-2):368-376. PubMed ID: 29886096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Macrolide Treatment Inhibits Pseudomonas aeruginosa Quorum Sensing in Non-Cystic Fibrosis Bronchiectasis. An Analysis from the Bronchiectasis and Low-Dose Erythromycin Study Trial.
    Burr LD; Rogers GB; Chen AC; Hamilton BR; Pool GF; Taylor SL; Venter D; Bowler SD; Biga S; McGuckin MA
    Ann Am Thorac Soc; 2016 Oct; 13(10):1697-1703. PubMed ID: 27464029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis.
    Aksamit T; Bandel TJ; Criollo M; De Soyza A; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R
    Contemp Clin Trials; 2017 Jul; 58():78-85. PubMed ID: 28495619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
    Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL
    J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis.
    Justo JA; Danziger LH; Gotfried MH
    Ther Adv Respir Dis; 2013 Oct; 7(5):272-87. PubMed ID: 23690368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin.
    Serisier DJ
    Drugs Today (Barc); 2012 May; 48(5):339-51. PubMed ID: 22645722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Treggiari MM; Retsch-Bogart G; Mayer-Hamblett N; Khan U; Kulich M; Kronmal R; Williams J; Hiatt P; Gibson RL; Spencer T; Orenstein D; Chatfield BA; Froh DK; Burns JL; Rosenfeld M; Ramsey BW;
    Arch Pediatr Adolesc Med; 2011 Sep; 165(9):847-56. PubMed ID: 21893650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial susceptibility of Pseudomonas aeruginosa before and after initiation of inhaled tobramycin in Bulgaria.
    Petrova G; Strateva T; Miteva D; Lazova S; Perenovska P
    J Infect Dev Ctries; 2016 Nov; 10(11):1265-1267. PubMed ID: 27886041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis.
    Wilson R; Aksamit T; Aliberti S; De Soyza A; Elborn JS; Goeminne P; Hill AT; Menendez R; Polverino E
    Respir Med; 2016 Aug; 117():179-89. PubMed ID: 27492530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis.
    Barker AF; Couch L; Fiel SB; Gotfried MH; Ilowite J; Meyer KC; O'Donnell A; Sahn SA; Smith LJ; Stewart JO; Abuan T; Tully H; Van Dalfsen J; Wells CD; Quan J
    Am J Respir Crit Care Med; 2000 Aug; 162(2 Pt 1):481-5. PubMed ID: 10934074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.
    Serisier DJ; Martin ML; McGuckin MA; Lourie R; Chen AC; Brain B; Biga S; Schlebusch S; Dash P; Bowler SD
    JAMA; 2013 Mar; 309(12):1260-7. PubMed ID: 23532242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
    Stass H; Delesen H; Nagelschmitz J; Staab D
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.